Strategic partnerships Newron has active development and commercialization agreements for evenamide with EA Pharma (Eisai subsidiary) for Japan and other Asian territories, and with Myung In Pharm for South Korea, indicating a proven partner-led expansion model that BD teams can leverage for co-promotion, regional licensing, and market access opportunities.

Phase III focus The ENIGMA-TRS Phase III program positions evenamide as a potential add-on therapy for treatment-resistant schizophrenia, presenting a clear near-term clinical and commercial opportunity for neuroscience-focused payers, specialty pharmacies, and neurology clinics seeking novel adjunctive options.

Lead product traction Xadago/safinamide is already marketed across major regions with multiple partners, providing a scalable template for regional market access, payer strategies, and distribution partnerships that can be extended to new territories or formats for evenamide.

Funding runway Recent financing rounds and a EUR 38 million raise, with a second tranche closing, bolster Newron’s financial position to advance the ENIGMA-TRS program, creating a favorable context for co-development investments, milestone-based deals, and strategic collaborations.

Leadership and exposure Active investor engagement and visible leadership participation in conferences signal readiness for investor and partner outreach; BD teams can capitalize on upcoming appearances and AGM activities to generate interest in collaboration, licensing, and regional partnerships.